EMAS is proud to publish position statements written by international experts on management of health conditions affecting midlife health and beyond. Recommendations are evidence based and suitable for integration into local guidelines worldwide
Maturitas. 21 December 2022
Maturitas. 2 February 2022
15 July 2021
Maturitas. 2020 Sep; 139:90-97
Maturitas. January 2020; 131:91-101
Maturitas. July 2017; 101:23-30
Maturitas. 2017 Jan; 95:65-71
Maturitas 2016; 89:63-72
Maturitas. 2016; 85: 79-81
Maturitas. 2016; 84:94-9
Maturitas. 2015; 81:88-92
Maturitas. 2015; 81:410-3
Maturitas. 2014; 79:481-486
Maturitas. 2014; 79:106– 116
Maturitas. 2014; 78:131–137
Maturitas. 2014; 78:67– 69
Maturitas. 2014; 77:85–89
Maturitas. 2013; 76:200–4
2012 Jan.; 71:83–8
Women’s health is increasingly recognized as a global health priority. Managing perimenopausal and postmenopausal health is a key issue worldwide. Therefore EMAS is making available to all short fact sheets to help women, healthcare and non healthcare professionals understand menopausal health.
Written by international experts, EMAS publishes clinical guides to provide models of care for health and allied health professionals dealing with menopause and midlife health. The guides are evidence-based and suitable for integration into local protocols worldwide.
Maturitas 2022; 163, P1-14
Maturitas 2021; 148: 55-61
Maturitas 2021; 143: 223–230
Maturitas 2020; 135: 82–88
Maturitas. 2018; 117:6–10
Maturitas. 2018; 110:118–123
Maturitas. 2018; 107:7-12
Maturitas. 2013; 75:181-90
Maturitas. 2013; 74:289-292
Maturitas. 2012; 73:171-4
Maturitas. 2012; 71:194-8
In 2020 there were 657 million women aged 45- 59, many contributing to the workforce throughout their menopausal years. Although the average age of the natural menopause is 51, it can occur earlier, either naturally or induced by surgery, radiotherapy and chemotherapy. While the menopause may cause no significant problems for some women, for others it is known to present considerable difficulties in both their personal and working lives. Workplace health and wellbeing frameworks and policies should therefore incorporate menopausal health as part of the wider context of gender and age equality and reproductive and post-reproductive health.
For a menopause-friendly workplace
To illustrate the 2021 EMAS Global Recommendations on menopause in the workplace
A general leaflet on menopause, its symptoms and its effects on the workplace and in private life
For employers and managers
For international and European statistics
On behalf of the International Menopause/Work Consortium [MEW0069] to the UK Parliament
Watch the video recordings
Research updates from 2015 to present
Guidelines from healthcare societies, personnel, and support organisations
Writing and publishing research papers, reviews and case reports 2020
Here are links to educational materials and papers for preparing submissions
2020, e00204. doi.org/10.1016/j.crwh.2020.e00204.
The global AWARE (Appropriate care for Women with AndRogen Excess) group is a panel of independent physicians with an expert interest in androgen excess. Their mission is to address the unmet need in androgen excess to ensure that women receive appropriate care. Since its formation in 2015, the AWARE group and its ongoing work is supported by Bayer. The group have created a number of useful resources that are available to download below. These resources aim to support healthcare professionals in the recognition, diagnosis and appropriate treatment of androgen excess. You may want to use these materials to support discussions with colleagues, for example, in a workshop setting.
Formation of the AWARE group and its ongoing work is supported and funded by Bayer AG.